Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) was $2.82 for the day, up 1.44% from the previous closing price of $2.78. In other words, the price has increased by $1.44 from its previous closing price. On the day, 11.96 million shares were traded. IOVA stock price reached its highest trading level at $2.83 during the session, while it also had its lowest trading level at $2.69.
Ratios:
Our analysis of IOVA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.00 and its Current Ratio is at 3.41. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 05 ’25 when Kirby Daniel Gordon bought 30,000 shares for $1.84 per share. The transaction valued at 55,200 led to the insider holds 30,000 shares of the business.
Puri Raj K. bought 5,600 shares of IOVA for $9,743 on May 23 ’25. The Chief Regulatory Officer now owns 206,852 shares after completing the transaction at $1.74 per share. On May 14 ’25, another insider, Vogt Frederick G, who serves as the Interim CEO & General Counsel of the company, bought 25,000 shares for $1.69 each. As a result, the insider paid 42,250 and bolstered with 374,646 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 1119449600 and an Enterprise Value of 871140672. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.47 while its Price-to-Book (P/B) ratio in mrq is 1.55. Its current Enterprise Value per Revenue stands at 3.479 whereas that against EBITDA is -2.318.
Stock Price History:
The Beta on a monthly basis for IOVA is 0.77, which has changed by -0.6342105 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, IOVA has reached a high of $8.15, while it has fallen to a 52-week low of $1.64. The 50-Day Moving Average of the stock is 23.52%, while the 200-Day Moving Average is calculated to be 14.34%.
Shares Statistics:
IOVA traded an average of 14.23M shares per day over the past three months and 14018900 shares per day over the past ten days. A total of 385.46M shares are outstanding, with a floating share count of 338.65M. Insiders hold about 14.69% of the company’s shares, while institutions hold 47.07% stake in the company. Shares short for IOVA as of 1764288000 were 118939462 with a Short Ratio of 8.36, compared to 1761868800 on 95415882. Therefore, it implies a Short% of Shares Outstanding of 118939462 and a Short% of Float of 32.33.
Earnings Estimates
. The current rating of Iovance Biotherapeutics Inc (IOVA) reflects the combined expertise of 9.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.14 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.99 and -$1.15 for the fiscal current year, implying an average EPS of -$1.08. EPS for the following year is -$0.61, with 9.0 analysts recommending between -$0.41 and -$1.03.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 11 analysts. It ranges from a high estimate of $93.3M to a low estimate of $74.27M. As of. The current estimate, Iovance Biotherapeutics Inc’s year-ago sales were $73.69MFor the next quarter, 11 analysts are estimating revenue of $82.76M. There is a high estimate of $94.2M for the next quarter, whereas the lowest estimate is $74.1M.
A total of 11 analysts have provided revenue estimates for IOVA’s current fiscal year. The highest revenue estimate was $270M, while the lowest revenue estimate was $251M, resulting in an average revenue estimate of $259.45M. In the same quarter a year ago, actual revenue was $164.07MBased on 11 analysts’ estimates, the company’s revenue will be $421.03M in the next fiscal year. The high estimate is $540.4M and the low estimate is $356.2M.
